Abstract: Cancer cells reprogram their metabolism to meet the demands of accelerated growth. Glucose is the primary source of energy for cancer cells, but under conditions of high-energy demand lipids and free fatty acids become increasingly important. PPAR is a member of the nuclear receptor superfamily and acts to regulate adipocyte differentiation and lipid metabolism. However, in many types of cancer, PPAR activity is elevated in order to increase production of adipogenic factors [1, 2]. -Tocotrienol is an isoform of vitamin E that displays potent anticancer activity [3] . Previous studies have shown that the antiproliferative effects of combined treatment of -tocotrienol with PPAR antagonists was associated with a reduction in PPAR activity, expression of PPAR and RXR, and suppression in Akt activation in MCF-7 and MBA-MB-231 human breast cancer cells [4] . The present study was conducted to determine the effects of combination treatment with these agents on adipogenic factor levels in rapidly proliferating human breast cancer cells. Western blot and qRT-PCR studies showed that combined treatment of -tocotrienol with PPAR antagonists not only suppressed the adipogenic proteins, C/EBP and SREBP-1c, but also decreased their target lipogenic enzymes, ap2, FAS, and HMGCoR. However, treatment effects were also observed in PPAR silenced breast cancer cells, indicating that these effects are mediated through PPAR -independent mechanism. These findings suggest the combined treatment of -tocotrienol with PPAR antagonist may have potential as a therapeutic strategy in the treatment of breast cancer.
INTRODUCTION
Cancer cells characteristically display an elevated metabolism and consume vast amounts of energy to support their growth and survival. Although, glucose is the primary energy source for cancer cells, during conditions of high-energy demand, lipids and free fatty acids can replace glucose as an important energy source. Adipocytes modulate lipid metabolism and are also involved in activating signaling pathways associated with promoting chronic inflammation [5] . Although it has not yet been firmly established that lipids derived from insulin-resistant adipocytes have a direct impact on cancer cell metabolism, evidence does suggest that activation of adipocytes appears to be involved in supporting growth and proliferation in malignant cells [5] . Peroxisome proliferator activated receptor (PPAR ), a member of the nuclear receptor superfamily, is expressed predominantly in adipose tissue, where it functions to regulates adipocyte differentiation and lipid metabolism [6] . Studies have shown that PPAR levels are elevated in many types of cancer tissues [1, 7, 8] . PPAR may function in cancer cells to increase production of adipogenic factors and lipogenic proteins in support of the high metabolic demands of cancer cells [2, 9] . Therefore, strategies *Address correspondence to this author at the College of Pharmacy, 700 University Avenue, University of Louisiana at Monroe, Monroe, LA 71209, USA; Tel: +1 3183421958; Fax: +1 3183421737; E-mail: sylvester@ulm.edu targeting the inhibition of PPAR may be beneficial in the treatment of cancer by acting to decrease adipogenic proteins and genes in rapidly proliferating cancer cells.
PPAR
regulates adipogenesis by activating families of transcription factors such as CCAATenhancer-binding proteins (C/EBP) and sterol regulatory element binding protein (SREBP; also called ADD1) [10, 11] . Studies have shown that of the three isoforms of C/EBP (C/EBP , C/EBP , and C/EBP ), PPAR directly regulates C/EBP and C/EBP to maintain a terminally differentiated state of adipocytes that is absolutely required for the function of fatselective enhancers such as adipocyte fatty acid binding protein (also called ap2) [12, 13] . In addition, PPAR regulates function of SREBP-1c and SREBP2, which are important regulators of fatty acid uptake and enhance fatty acid (FA) synthesis by modulating activity of key lipogenic enzymes such as FA synthase (FASN) and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCoR) [14] [15] [16] . Investigations have also shown that specific C/EBP and SREBP isoforms are over expressed in many types of cancers in order to compensate for the elevated energy demand displayed by these cells [17, 18] .
-Tocotrienol is a naturally occurring isoform within the vitamin E family of compounds that displays potent anticancer activity [19, 20] by suppression of growthfactor-dependent mitogenic signaling [21, 22] . In vitro studies have previously shown that mammary tumor cells exposed to -tocotrienol treatment display a significant reduction in 3-hydroxy-3-methylglutaryl-CoA reductase activity through posttranscriptional downregulation of this enzyme [23] . Additional studies showed that -tocotrienol inhibits adipogenesis in 3T3-L1 preadipocytes by suppressing insulin-induced ap2 protein and Akt phosphorylation [24] , and reduce SREBP expression in human fibroblasts [25] .
The antiproliferative effects of -tocotrienol may be due to changes in PPAR activity [26] , Studies conducted in human breast cancer cells showed that the antiproliferative effects resulting from combined treatment of -tocotrienol with PPAR antagonists (GW9662 or T0070907) was associated with a reduction in PPAR expression and activity [4] . However, the effects of these combination treatments on lipogenic enzymes have not yet been determined. Therefore, studies were conducted to determine the effects of combination treatment of -tocotrienol with PPAR antagonists on C/EBP and SREBP isoforms and their target lipogenic genes. In addition, experiments were conducted to understand whether these effects are mediated by PPAR -dependent versus PPAR -independent mechanisms.
MATERIALS AND METHODS

Reagents and Antibodies
Unless stated otherwise, all reagents were purchased from Sigma Chemical Company (St. Louis, MO). Isolated -tocotrienol (>98% purity) used in experimentation was acquired from First Tech International Ltd (Hong Kong). The PPAR antagonists, GW9662 and T0070907, were purchased from Cayman Chemicals (San Diego, CA). Cells grown in culture were maintained in media that contain fetal bovine serum (FBS) that was purchased from American Type Culture Collection (Manassas, VA). Primary antibodies used in Western blot analysis foractin, PPAR , C/EBP , C/EBP , lipin 1, FASN, ap2, and HMGCoR were purchased from Cell Signaling Technology (Beverly, MA), while the primary antibody directed against SREBP-1c was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Secondary antibody used in Western blot analysis was goat antirabbit and was purchased from PerkinElmer Biosciences (Boston, MA).
Cell Lines and Culture Conditions
The human breast cancer cell lines, MCF-7 and MDA-MB-231, used in experimentation were purchased from American Type Culture Collection (Manassas, VA). MCF-7 is an estrogen-receptorpositive, whereas MDA-MB-231 is an estrogenreceptor negative, ductal epithelial cancer breast cell. Both breast cancer cell lines were maintained in a 1:1 mixture of modified Dulbecco's modified Eagle's medium (DMEM) and Ham's F12 medium supplemented with 10% fetal bovine serum, 10μg/ml insulin, 100 U/ml penicillin, 0.1 mg/ml streptomycin. Cells were maintained in a humidified incubator at 37 o C in a 95% air and 5% CO 2 environment. Prior to experimentation, cells were harvested for subculturing, media was removed and cells were twice washed with sterile Ca 2+ -and Mg 2+ -free phosphate-buffered saline (PBS). Cells were then incubated in 0.05% trypsin containing 0.025% EDTA in PBS for 5 min at 37°C. Afterward, the now released cells were collected by centrifugation, and then resuspended in serum containing media. The number of harvested cells was then calculated using a hemocytometer as previously described in detail [19] .
Experimental Treatments
All isoforms of vitamin E are highly lipophilic. Therefore, in order to dissolve -tocotrienol into the aqueous culture media, it must first be suspended in a sterile 10% bovine serum albumin (BSA) solution [19, 20] . This is accomplished by first taking a known amount of purified -tocotrienol and dissolving it in 100 μL of 100% ethanol. Once dissolved, this -tocotrienol/ethanol solution is then added to a small volume of sterile 10% BSA in water to produce a final 10 mM -tocotrienol/BSA stock solution. This stock solution is then incubated overnight at 37°C with continuous shaking. From this stock solution, different concentration of -tocotrienol containing treatment media is prepared. Likewise, stock solutions of the highly lipophilic PPAR antagonist, GW9662 and T0070907, were prepared by dissolving these agents in sterile dimethyl sulfoxide (DMSO), and then the appropriate amount of this stock solution was then added directly to treatment media. Ethanol and/or DMSO can induce toxic effects to cells in culture if concentrations reach levels greater than 1%. Therefore, as a treatment control, the levels ethanol and/or DMSO were adjusted in all control and treatment media so that exposure to these agents was the same for all cells in a particular experiment. The final concentration of ethanol and/or DMSO within any given experiment was always less than 0.1%.
Growth Studies
In dose-response studies examining the antiproliferative effects of the various treatments, MCF-7 and MDA-MB-231 breast cancer cells were isolated, resuspended and counted as described above in section 2.2. Cells were then seeded at a density of 1x10 4 cells suspended in 100 L control media into each well of a 96-well culture plate, returned to the incubator and allowed to adhere to the bottom of the plate. The next day, cells were divided into different treatment groups and the original media was removed. Cells were then washed with 100 L of sterile PBS and then all wells received 100 L of their respective treatment media containing either 0-12 μM GW9662, T0070907 or 0-6 μM -tocotrienol alone or combination and then plates were returned to the incubator. Treatment media was replaced with fresh media every other day throughout the 4-day experimental period.
Measurement of Viable Cell Number
MCF-7 and MDA-MB-231 breast cancer cell number was determined in 96-well culture plates (8 wells/group) by the 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyl tetrazolium bromide (MTT) colorimetric assay using a modification of the method previously described in detail [19, 20] . On the day of assay, treatment medium was replaced with fresh control medium containing 0.5 mg/mL MTT, and cells were returned to the incubator for 3 h. At the end of the incubation period, treatment media was removed, and the MTT crystals were dissolved in 100 μL of DMSO. The optical density of each sample was read at 570 nm on a microplate reader (Spectracount; Packard Bioscience Company, Meriden, CT) that was zeroed against a blank prepared from cell-free cultures. The number of cells/well was calculated against a standard curve prepared by plating various concentrations of cells, as determined by hemocytometer, in triplicate at the start of each experiment. Previous studies showed that -tocotrienol treatment does not affect the specific activity of the MTT assay [19, 20] .
Western Blot Analysis
In studies measuring treatment effects on PPAR signaling protein or lipogenic factor expression by Western blot analysis, 1x10 6 MCF-7 or MDA-MB-231 breast cancer cells were resuspended in 10 mL of control medium and plated in 100 mm culture plates.
Plates were then returned to the incubator to allowed cells to attach to the bottom of the plate. The next day, media was removed and the cells were washed with 10 mL sterile PBS, divided into the various treatment groups and fed 10 mL of their respective treatment media. Cells were then returned to the incubator. Fresh media was replaced every other day for the remainder of the 4-day experimental period. Afterwards, cells were twice washed with sterile PBS, and isolated with trypsin as described above. Whole cell lysates were prepared by resuspending cells in lysis buffer, then boiled for 5 min, sonicated, microcentrifuged at 4 o C and the supernatant was collected [22, 27, 28] . The protein concentration in each sample was determined using a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Equal amounts of protein from each sample in a given experiment was then loaded onto SDSpolyacrylamide minigels and electrophoresed through a 15% resolving gel. Separated proteins on each gel were then transferred to a polyvinylidene fluoride (PVDF) membrane at 30 V for 12-16 h at 4°C (PerkinElmer Lifesciences, Wellesley, MA) in a TransBlot Cell (Bio-Rad, Hercules, CA) according to the method of Towbin et al. [29] . Nonspecific antibody binding sites were blocked on each transblotted membranes by incubating membranes in 2% BSA in 10 mM Tris HCl containing 50 mM NaCl and 0.1% Tween 20 pH 7.4 (TBST) for 2 h, followed by an incubation with specific primary antibodies against PPAR , C/EBP , C/EBP , SREBP-1c, lipin 1, FASN, ap2, HMGCoR or -actin, diluted 1:500 to 1:5000 in TBST/2% BSA for 2 h. Afterwards, membranes are washed 5 times with TBST followed by incubation with their respective horseradish peroxide-conjugated secondary antibodies diluted 1:3000 to 1:5000 in TBST/2% BSA for 1 h, and then washed again with TBST. Specific target protein bands on each membrane were then visualized by chemiluminescence (Pierce, Rockford, IL) according to the manufacturer's instructions. Images were obtained using a Syngene Imaging System (Frederick, MD). The visualization of -actin in each sample was used as a control standard to verify the equal sample loading occurred in each lane. Protein bands images were then acquired and densitometric analysis was performed with the Kodak molecular imaging software version 4.5 (Carestream Health Inc, Rochester, NY). All experiments were repeated at least three times. Representative Western blot images from each experiment are shown in the Figures.
Transient Transfection and Luciferase Reporter Assay
In transfection and reporter assays, 2x10 4 reagent (Invitrogen, Grand Island, NY) and returned to the incubator. Following a 6 h incubation period, the transfection media was removed, cells were washed in 100 L sterile PBS, and then exposed to 100 μL of control or treatment media and returned to the incubator, and fresh media was provided every other day. After a 4-day experimental period, cells were lysed with 75 μL of passive lysis buffer and treated according to manufacturer's instructions using dual-glo luciferase assay system (Promega, Madison, WI). Renilla activity in each sample was used to normalize luciferase activity. Experimental results are represented as the mean-fold change in activity observed in treated cells, as compared to the activity observed in vehicle-treated control cells.
Quantitative Real-Time PCR
In qPCR studies, 2x10 5 MCF-7 or MDA-MB-231 breast cancer cells were resuspended in 2 mL of control medium and plated in each well of a 6-well culture plate and then returned to the incubator to allowed cells to attach to the bottom of the plate. The next day, cells were divided into different treatment groups (3 wells/group) culture media was removed, washed with sterile PBS, then fed fresh media containing their respective treatments that included 0-6.4 μM GW9662, 0-6.4 μM T0070907 or 2-3μM -tocotrienol alone or in combination and then return to the incubator. Cells were fed fresh media every other day during the 4-day culture period. Total RNA was extracted using Applied Biosystems (Carlsbad, CA) RNA kit according to the manufacturer's instructions. First-strand cDNA was generated from total RNA for each sample using the cDNA kit from Applied Biosystems (Carlsbad, CA) according to the manufacturer's instructions. Taqman PCR probes and gene-specific primer pairs were generated for PPAR , RXR, C/EBP , SREBP-1c, and GAPDH using Integrated DNA technologies (Coralville, IA). qRT-PCR was performed on an Applied Biosystems (Carlsbad, CA) Prism 7900 Sequence Detection System. Reactions were prepared in triplicate for each gene using Taqman gene expression assays. During thermal cycling, the threshold cycle (C t ) is defined as the cycle number when amplification of a specific PCR product is detected. The average C t value of GAPDH was subtracted from average C t value of target genes (PPAR , RXR, C/EBP , SREBP-1c) to normalize the amount of sample RNA added to the reaction. Relative quantification describes the fold change in expression of a gene of interest in a test sample relative to a calibrator sample. With the comparative C t ( C t ) method, the level of the target gene mRNA in treatment samples relative to control samples was determined.
Statistical Analysis
Differences among the various treatment groups in growth studies and Western blot studies were determined by analysis of variance followed by Dunnett's multiple range test. Differences were considered statistically significant at a value of P<0.05.
RESULTS
Antiproliferative Effects of -Tocotrienol and PPAR Antagonists (GW9662 or T0070907) when Given Alone and in Combination
Treatment with 3-4 M -tocotrienol, or 3.2-6.4 M GW9662 or T0070907 was found to significantly inhibit growth of MCF-7 cells in a dose-responsive manner as compared to cells in the vehicle treated control group (Figure 1A and B) . However, when combined with a subeffective dose (3.2 M) of the PPAR antagonist, GW9662 and T0070907, the growth inhibitory effects of 1-4 M -tocotrienol was significantly enhanced in MCF-7 breast cancer cells (Figure 1C and D) . Similarly, treatment with 4-6 M -tocotrienol, or 6.4-12 M GW9662 or T0070907 was found to significantly inhibit growth of MDA-MB-231 cells in a dose-responsive manner as compared to cells in the vehicle treated control group (Figure 1E and F) . However, the growth inhibitory effects of 3-6 M -tocotrienol was significantly enhanced when given in combination with a subeffective dose (6.4 M) of the PPAR antagonists, GW9662 and T0070907, in MDA-MB-231 breast cancer cells (Figure 1G and H) . levels (Figure 2A and B) and PPRE mediated reporter activity (Figure 2C and D) as compared to the vehicle treated controls. Treatment with 3.2 μM GW9662 or T0070907 alone in MCF-7 cells or 6.4 μM GW9662 or T0070907 alone in MDA-MB-231 cells had little or no effect on PPAR or RXR mRNA levels (Figure 2A and B) and PPRE mediated reporter activity (Figure 2C and  D) . However, combined treatment with similar doses of -tocotrienol and GW9662 or T0070907 resulted in a relatively significant decrease in PPAR and RXR mRNA levels (Figure 2A and B) and PPRE mediated reporter activity in MCF-7 and MDA-MB-231 breast cancer cell lines as compared to vehicle treated-control cells (Figure 2C and D) .
Effects of -Tocotrienol and PPAR Antagonists (GW9662 and T0070907) Given Alone or in Combination on C/EBP and C/EBP Levels
Western blot analysis shows that treatment with 2 μM (MCF-7 cells) or 3 μM (MDA-MB-231 cells) -tocotrienol and 3.2 μM (MCF-7 cells) or 6.4μM (MDA-MB-231 cells) of the PPAR antagonists, GW9662 or T0070907 alone did not induce change in expression of C/EBP and C/EBP as compared to the vehicle treated controls (Figure 3A, B, C, and D) . However, combined treatment with these same doses oftocotrienol and GW9662 or T0070907 caused a significant reduction in levels of C/EBP without any change in the expression of C/EBP in both MCF-7 and MDA-MB-231 cells as compared to vehicle-treated controls ( Figure 3A, B, C, and D) .
Effects of -Tocotrienol and PPAR Antagonist GW9662 and T0070907 Given Alone or in Combination on SREBP-1c, SREBP 2, and Lipin 1 Levels
Western blot analysis shows that treatment with 2 μM (MCF-7 cells) or 3 μM (MDA-MB-231 cells) -tocotrienol and 3.2 μM (MCF-7 cells) or 6.4 μM (MDA-MB-231 cells) of the PPAR antagonists, GW9662 or T0070907 alone did not induce change in the expression of SREBP-1c, SREBP 2 and lipin 1 as compared to the vehicle treated controls (Figure 4A, B,   C, and D) . However, combined treatment with these same doses of -tocotrienol and GW9662 or T0070907 caused a significant reduction in levels of SREBP-1c and lipin 1 without change in the expression of SREBP 2 in both MCF-7 and MDA-MB-231 cells as compared to vehicle-treated controls ( Figure 4A, B, C, and D) . MB-231 cells) of the PPAR antagonists, GW9662 or T0070907 alone did not induce any change in the mRNA levels of C/EBP and SREBP-1c (Figure 5A  and B) . However, combined treatment with these same doses of -tocotrienol and GW9662 or T0070907 caused a significant reduction in mRNA levels of C/EBP and SREBP-1c in both MCF-7 and MDA-MB-231 cells as compared to vehicle-treated controls (Figure 5A and B) .
Effects of -Tocotrienol and PPAR Antagonist GW9662 and T0070907 Given Alone or in Combination on FAS, ap2, and HMGCoR Levels
Western blot analysis shows that treatment with 2 μM (MCF-7 cells) or 3 μM (MDA-MB-231 cells) -tocotrienol and 3.2 μM (MCF-7 cells) or 6.4 μM (MDA-MB-231 cells) of the PPAR antagonists, GW9662 or T0070907 alone did not induce any change in expression of FAS, ap2 and HMGCoR as compared to the vehicle-treated controls ( Figure 6A, B, C, and D) . However, combined treatment with these same doses of -tocotrienol and GW9662 or T0070907 caused a significant reduction in levels of FAS, ap2, and HMGCoR in both MCF-7 and MDA-MB-231 cells as compared to vehicle-treated controls (Figure 6A, B, C,  and D) . Western blot analysis showed that treatment with 2 μM -tocotrienol (MCF-7) or 3 μM (MDA-MB-231 cells) -tocotrienol and 3.2 μM (MCF-7 cells) or 6.4 μM (MDA-MB-231 cells) of the PPAR antagonists, GW9662 or T0070907 alone did not induce any change in the expression of C/EBP and SREBP-1c in comparison to vehicle treated controls or cells transfected with scrambled RNA (Figure 7A, B, C, and D) . However, combined treatment with these same doses oftocotrienol and GW9662 or T0070907 caused a reduction in levels of effects in the expression of C/EBP and SREBP-1c as compared to vehicle treated controls or cells transfected with scrambled RNA in PPAR positive MCF-7 and MDA-MB-231 breast cancer cells (Figure 7A, B, C, and D) .
Effects of -Tocotrienol and PPAR
DISCUSSION
Previous studies showed that combined treatment of -tocotrienol with PPAR antagonists (GW9662 and T0070907) resulted in a synergistic inhibition of MCF-7 and MDA-MB-231 breast cancer cell growth that was mediated by a direct decrease in PPAR activity and expression [4] . Results in the present study extend these previous findings by demonstrating that combination treatment effects induced by -tocotrienol and PPAR
antagonists is associated with a There is compelling evidence indicating the important role of PPAR family members in lipid sensing and utilization and to aid in cellular protection against lipid excess. Particularly, PPAR plays a role in fatty acid uptake and transport (e.g. by adipocytes), and acts to control inflammation that can arise from increased adipocyte differentiation and proliferation [30, 31] . However, cancer cells characteristically display high levels of lipids and lipid precursors together with increased levels of PPAR [32] . It has been hypothesized that PPAR may act to promote the growth and survival of these highly proliferating malignant cell populations [32] . Numerous investigations have established that -tocotrienol is a potent anticancer agent that inhibits the growth of mouse [3, 33] and human [34, 35] breast cancer cells. In addition, -tocotrienol has been shown to inhibit adipogenesis in 3T3-L1 preadipocytes by suppressing insulin-induced Akt phosphorylation [24] . Studies have also shown that combined treatment of -tocotrienol with other traditional chemotherapies results in synergistic or additive antiproliferative effects against various types of cancer cells [3, 33] . Results in the present study further emphasize the importance of down-regulation of PPAR in cancer cells as a potential therapeutic strategy [1, 8, 36] .
PPAR regulates adipogenesis with the help of C/EBP family of proteins [37] . Studies conducted on mammary tumor samples show that increased expression of PPAR results in a corresponding increase in C/EBP , and subsequent increase in cancer cell proliferation [38] . In contrast, other studies showed that C/EBP was not involved in cancer progression [17] . Additional reports have shown that PPAR regulates the SREBP family of transcription factors that are associated with adipocyte differentiation, cholesterol synthesis, and lipid metabolism [39, 40] . PPAR induces ectopic expression of AAD/SREBP-1c and a related transcription factor SREBP 2 in 3T3L1 cells and HepG2 cells [41] . SREBP-1c and SREBP 2 in turn regulate lipid metabolism by activating FASN [42] . Studies show that there is an increased expression of SREBP-1c and FASN mRNA levels, while SREBP-2 showed less variation in MCF-7 breast cancer cells [18] . Furthermore, targeting SREBP-1c and FASN has recently been recommended as a treatment against breast cancer [43] . PPAR regulates nuclear translocation of SREBP-1c by controlling lipin 1, a phosphatidic acid phosphatase in 3T3-L1 adipocytes [44] . Lipin 1 is also associated with insulin sensitivity and glucose metabolism in human samples [45] . The decreased level of lipin 1 in the present study suggests that combination treatment may also have a potential role in decreasing glucose metabolism in breast cancer cells. Additional experiments are needed to confirm this hypothesis.
A study conducted by Sim et al., showed that PPAR antagonist, GW9662 decreased levels of SREBP and HMGCoR to inhibit cholesterol synthesis in human glial progenitor cells. This study suggests the potential role of PPAR antagonists in inhibiting cholesterol synthesis [46] . HMGCoR is the rate-limiting enzyme in mevalonate pathway for cholesterol synthesis [47] . Interestingly, the mevalonate pathway is constitutively active in malignant cells due to elevated and unregulated HMGCoR activity [23] . Tocotrienols appear to reduce HMGCoR activity by triggering both the retention of SREBP-1c on the endoplasmic reticulum and the degradation of HMGCoR, thereby inducing the reduction in both mRNA and protein HMGCoR levels [25, 48, 49] . Furthermore, combined treatment with subeffective doses of -tocotrienol and various statins (HMGCoR inhibitors) was found to significantly inhibit +SA mammary tumor cell growth associated with a large reduction in HMGCoR expression [23] .
PPAR induced expression of C/EBP is associated with an increase in adipogenesis and synthesis of adipocyte-selective ap2 (fatty acid binding protein) [50] . This adipocyte-selective protein strikes a balance between availability of metabolic resources and the control of inflammatory responses. Studies have shown that these proteins are heavily and aberrantly expressed in tumors where they appear to regulate growth and survival responses. Therefore, ap2 offers targeting opportunities for the development of therapeutic treatment for not only cancer, but also other metabolic diseases [51] . Apart from its role as an adipogenic protein, some studies suggest that ap2 may also be involved in breast cancer cell invasion and metastasis, and suggest that ap2 might be used as a diagnostic marker for breast cancer [52] . Other studies have shown that anticancer effects induced by PPAR antagonists are mediated, in part, by PPARindependent mechanisms [53, 54] . These findings are further supported by results in the present study demonstrating that PPAR ligands mediate adipogenesis through PPAR -independent mechanisms.
In summary, results in the present study show that combined treatment of -tocotrienol with PPAR antagonists suppress adipogenic proteins and their target genes C/EBP , SREBP-1c, ap2, FAS, and HMGCoR. Furthermore, these combination treatment induced effects were found to occur independently of PPAR expression and activity. Taken together, these findings demonstrate the potential importance of combined treatment of -tocotrienol with PPAR antagonists as a therapeutic strategy in treatment of breast cancer.
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